MedTrace Logo

DETERMINATION OF THE CELL OF ORIGIN (COO) in LDCGB

NCT04244331 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 159

Last updated 2024-02-26

No results posted yet for this study

Summary

This is a prospective, multicenter study, without any therapeutic intervention that will consist of the analysis of the results of the determination of the COO of all the patients diagnosed with LDCGB in the Spanish hospitals of GELTAMO that adhere to the project. The determination of the COO will be carried out prospectively at the Genomic Unit of the Hospital Clínic de Barcelona (IDIBAPS), where the histological samples of the patients will be sent for this purpose.

The main study variable will be the description of the COO (germ-center origin \[GCB\], activated \[ABC\], NOT DETERMINABLE, NOT VALUABLE)

Conditions

  • CCO

Interventions

DIAGNOSTIC_TEST

CCO

Determination of COO in tumor biopsies from patients with GBDD using the Lymph2Cx assay using NanoString tectology

Sponsors & Collaborators

  • Institut d'Investigacions Biomèdiques August Pi i Sunyer

    collaborator OTHER

  • Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-01
Primary Completion
2019-05-01
Completion
2020-03-01

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04244331 on ClinicalTrials.gov